Drug Development

Articles

The acquisition expands Sartorius Stedim Biotech’s service portfolio.

Sartorius Stedim Biotech Acquires BioOutsource

The Ph. Eur. contemplates adding specifications for sub-visible particles in eye drops and eye lotions to its monograph.

European Pharmacopoeia Seeks Comments on Eye Preparations Monograph

The single-use clarification system eliminates centrigues; harvesting can be performed in one step; and process robustness and predictability are ensured.

Sartorius Stedim Biotech Launches New Single-Use Harvesting Technology for High Cell Density Cultures

The license approval marks another milestone in Aptar Pharma’s ongoing service development to provide large-scale production services to customers.

Aptar Pharma Granted License to Deliver Preservative-Free Multi-Dose Systems to China

As the prevalence of falsified medicines continues to increase, Switzerland is taking measures to secure its supply chain such as the implementation of serialization.

DBV Technologies Receives FDA Breakthrough Therapy Designation for Peanut Allergy Treatment

Aptar Pharma has partnered with Shanghai Sine Promod Pharmaceutical to develop and launch its new budesonide dry powder inhaler (DPI), which features Aptar Pharma’s user-friendly and cost-effective Twister DPI.

Shanghai Sine Promod Pharmaceutical Chooses Aptar Pharma’s Twister DPI for Asthma Therapy

GlaxoSmithKline announces global vaccines research and design facility to be based in Rockville, MD, USA.

GSK Announces US Vaccine R&D Center

NIH announced positive safety results from the vaccine, VSV-ZEBOV, and found that all patients in the study experienced a strong antibody response.

NIH Announces Positive Results for Experimental Ebola Vaccine

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Emerging controlled-release technologies could lead to more effective therapies in the near future.

Will Advances in Controlled Release Open Up New Drug Delivery Opportunities?

James P. Agalloco is the president of Agalloco & Associates, P.O. Box 899, Belle Mead, NJ 08502, tel. 908.874.7558, jagalloco@aol.com. He is also a member of Pharmaceutical Technology’s editorial advisory board.

The Human Microbiome Project has increased our understanding of the relationship between humans and microorganisms. The authors offer a new perspective on how this knowledge should be considered in setting standards for pharmaceutical quality control in microbiology.

Formulation and Drug Delivery